Compare Enveric Biosciences Inc (ENVB) vs Lamb Weston Holdings Inc (LW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Lamb Weston Holdings Inc — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while Lamb Weston Holdings Inc trades at $49.45 (market cap $6.63B). The key difference: Lamb Weston Holdings Inc is far larger — about 991× Enveric Biosciences Inc's market cap, and Lamb Weston Holdings Inc pays a 3.16% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Lamb Weston Holdings Inc for 66 Days on average.
| ENVB | LW | |
|---|---|---|
Market Cap | $6.69M | $6.63B |
Volume | 41,141 | 3,860,427 |
Sector | Health | Consumer Staples |
52-Week High | $10.80 | $66.57 |
52-Week Low | $1.27 | $38.48 |
Typical Hold Time | 14 Days | 66 Days |
Enterprise Value | -$1.60M | $10.42B |
Dividend Yield | — | 3.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
Lamb Weston (LW) trades at $49.46, up 3.24% today, with a bullish technical signal and strong earnings beat history. The stock shows robust fundamentals with a P/E of 26.28 and ROE of 14.17%, supported by consistent revenue growth and positive cash flow trends. Recent news highlights cost savings exceeding $100M and upcoming Q1 earnings, while analyst consensus leans toward a hold with a $53.71 price target.
The outlook for LW is cautiously optimistic, with potential upside from margin recovery and earnings beats, but risks include profit margin volatility and legal scrutiny. Investors should weigh the stock's valuation against operational execution and market sentiment shifts ahead of earnings reports.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Lamb Weston Holdings Inc
Lamb Weston is the world's second-largest producer of branded and private-label frozen potato products, such as French fries, sweet potato fries, tater tots, diced potatoes, mashed potatoes, hash browns, and chips. The company also has a small appetizer business that produces onion rings, mozzarella sticks, and cheese curds. Including joint ventures, 63% of fiscal 2022 revenue was U.S.-based, with the remainder stemming from Europe, Canada, Japan, China, Korea, Mexico, and several other countries. Lamb Weston's customer mix is estimated 58% quick-serve restaurants, 19% full-service restaurants, 8% other food services (hotels, commercial cafeterias, arenas, schools), and 16% retail. Lamb Weston became an independent company in 2016 when it was spun off from Conagra.
Read more on LW →
